Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration
Part of paid clinical trials in Palo Alto, California.
- Sponsor
- Stanford University
- Study ID
- NCT01526070
- Status
- Completed
Conditions
- Exudative Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
Study Details
Over the last several years, the standard of care for wet macular degeneration has become treatment with intravitreal injections of ranibizumab (Lucentis, Genentech), administered as frequently as every 4 weeks. In contrast, clinical trials of a soluble VEGF receptor, Aflibercept/VEGF Trap-Eye (Eylea, Regeneron Pharmaceuticals) have demonstrated maintained anatomic and visual improvement with many fewer injections (typically monthly injections for 3 months, followed by every-other-month injections, and as few as 5 injections a year). The purpose of this study is to determine whether patients who have switched from ranibizumab to VEGF Trap-Eye have comparable results.
Key Dates
- Start date
- Jan 31, 2012
- Status verified
- Nov 2014
- Primary completion
- Jul 31, 2014
- Completion
- Jul 31, 2014
Study Design
- Enrollment
- 142 participants (actual)
Arms
- Arm: Patients with Exudative Age-Related Macular DegenerationPatients with eAMD who received intravitreal thearpy
Primary Outcome Measure
Visual Acuity [ Time Frame: 1 year ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Byers Eye Institute at Stanford | Palo Alto | California | 94303 | - |